Guardian Pharma Reports Q3 2026 Growth and Raises Full-Year Guidance
Guardian Pharma (GRDN) reported third-quarter 2026 results characterized by strong profitability growth despite a slight decline in total revenue. While reported revenue fell 1.7% to $371.1 million due to drug price reductions mandated by the Inflation Reduction Act, adjusted revenue grew in the high single digits when excluding those federal impacts. The company saw significant margin expansion, with Adjusted EBITDA rising 24% year-over-year to $33.9 million. Driven by increased prescription volumes and successful purchasing initiatives, management raised its full-year guidance for both revenue and Adjusted EBITDA. The company maintains a strong balance sheet with zero long-term debt and continues to focus on expanding its market share within the assisted living pharmacy sector through organic growth and strategic acquisitions.
Tickers: $GRDN
Topics: earnings report EBITDA guidance upgrade revenue growth